Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21082771 | 1.00 | MEN1 (0.41) | MEN1KMT2ADPP4SIGMAR1METAP2 | |
| SCHEMBL13675441 | 0.94 | MEN1 (0.36) | MEN1KMT2ADPP4SIGMAR1 | |
| SCHEMBL4716845 | 0.89 | — | — | |
| SCHEMBL13502998 | 0.82 | CTSD (0.34) | MEN1KMT2ADPP4 | |
| SCHEMBL12632154 | 0.82 | ANPEP (0.33) | — | |
| SCHEMBL12022913 | 0.81 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL8086449 | 0.80 | CTSD (0.32) | — | |
| SCHEMBL13502927 | 0.80 | METAP2 (0.36) | KMT2ADPP4METAP2PRKCIREN | |
| SCHEMBL10305516 | 0.79 | DPP4 (0.43) | DPP4SIGMAR1 | |
| SCHEMBL12022727 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190829-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | MEN1 2924/4885KMT2A 4252/4885DPP4 28/4885 |
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | MEN1 2445/4885KMT2A 3830/4885DPP4 11/4885 |
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | MEN1 2924/4885KMT2A 4252/4885DPP4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.